Live Breaking News & Updates on Oncology Business Group At Eisai Inc

Stay updated with breaking news from Oncology business group at eisai inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Gregory Lubiniecki , Nikki Sullivan , Peter Dannenbaum , Melissa Moody , Corina Dutcus , Merck Research Laboratories , Oncology Clinical Research , Eisai Co Ltd , Merck Co Inc , European Union , Clinical Research , Society Of Gynecologic Oncology , Oncology Business Group At Eisai Inc , Results From Pivotal Phase , Advanced Endometrial Carcinoma , New England Journal , Gynecologic Oncology , Vice President , Merck Research , Senior Vice President , Oncology Business Group , Significantly Improved Progression Free Survival , Acn Newswire ,

Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma

Published in the New England Journal of MedicineTOKYO, Jan 20, 2022 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced ....

United States , Gregory Lubiniecki , Nikki Sullivan , Peter Dannenbaum , Melissa Moody , Corina Dutcus , Merck Research Laboratories , Oncology Clinical Research , Eisai Co Ltd , Merck Co Inc , European Union , Clinical Research , Society Of Gynecologic Oncology , Oncology Business Group At Eisai Inc , New England Journal , Gynecologic Oncology , Vice President , Merck Research , Senior Vice President , Oncology Business Group , Significantly Improved Progression Free Survival ,

Dr. Richard Woodman Appointed Chief Clinical Officer of the Oncology Business Group at Eisai Inc.

Share this article
WOODCLIFF LAKE, N.J., Jan. 20, 2021 /PRNewswire/
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Dr. Richard Woodman as Chief Clinical Officer (CCLO) of its Oncology Business Group. In this role, Dr. Woodman will have full oversight and responsibility for the strategic and operational leadership of the company s global oncology clinical development functions, including clinical research, clinical operations, imaging, medical writing, data services, biostatistics and regulatory strategy. He will also serve as a member of the Oncology Executive Leadership team.
Dr. Richard Woodman
Dr. Woodman, who has 18 years of pharmaceutical experience in several different functional areas at both large and small biotech organizations, will lead the clinical team s development of Eisai s next generation oncology products by managing the design protocols and implementation of all oncology clinic ....

United States , New Jersey , North Carolina , Patricia Councill , Global Medical Affairs , Head Of Research , Division Of Hematology Hematological Malignancies , Eisai Inc , Eisai Co Ltd , Us Oncology Clinical Development , Research Institute , Department Of Experimental Medicine , University Of Calgary , Oncology Business Group At Eisai Inc , Immunology Research Group , Takashi Owa , Chief Medicine Creation Officer , Chief Discovery Officer , Oncology Business Group , Chief Medical Officer , Onconova Therapeutics , Clinical Development , Medical Affairs , Franchise Head , Global Medical , Senior Medical Director ,